SureTrader Nadex Advertisement PGUS
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

ELTP RSS Feed
Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Mocha Jet, Drugdoctor, joseytheoutlawwales, lasers, John_Langston, IB_
Search This Board: 
Last Post: 3/24/2017 11:56:20 PM - Followers: 829 - Board type: Free - Posts Today: 0

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

 
Elite’s website can be found by going to http://www.elitepharma.com


How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.
 


 

Recent Press Releases:

Oct 21, 2015
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=79416&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0

Aug 10, 2015
Elite Pharmaceuticals Reports Record Revenues for First Quarter of Fiscal Year 2016
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78453&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Aug 3, 2015
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78262&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 16, 2015
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77581&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77479&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0


More information can be found by going to Elite’s investor section:  http://ir.elitepharma.com/press_releases
Highlights From Last Quarter:
 
Second quarter ending September, 2015
Consolidated revenues for the second quarter of fiscal 2015 was $2.7M, all of which came from Elite's generic operation. An increases of 30% over last quarter's generic revenues. Generic revenue continues to grow with new highs being set  8 out of the 10 last quarters. The cost of revenue for this quarter totals $1.4M, for a gross profit of $1.3M. Overall expenses for the quarter total $5.3M with $4.2M going towards the development of Elite’s proprietary abuse-deterrent opioid product,ELI-200.
 
Business Update
The first product to utilize Elite's abuse deterrent technology, ELI-200, has successfully completed Phase III studies. The Company believes that it will be able to file a New Drug Application (NDA) with the FDA during this calendar year. When this application is accepted by the FDA it will be granted expedited review by the FDA,the company estimates that approval could be achieved in calender Q2\2016. Shareholders will be notified when the FDA accepts the ELI-200 NDA which is estimated to be in the first or second week in Jan, 2016.
 
Common shares issued pursuant to the strategic alliance agreement with Epic Investments LLC.
As per the Epic Strategic Alliance, Elite is entitled to 15% of the profits achieved from the commercial sales of Epic's immediate release oxycodone tablets, for a 10 year period commencing on the date of first commercial shipment and Epic is to receive 3 million shares of Common Stock upon approval by the FDA of the ANDA.
 

Financials:
 
 
 

Products:
 
http://www.elitepharma.com/products/

Leadership:

President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.


Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222
Email: [email protected]

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755
 


Miscellaneous Links:

SEC Filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001053369&owner=include

FDA website: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails

Clinical Trials.Gov: https://www.clinicaltrials.gov/




 


  Using the industry average PE\Ratio of 15, an over exaggerated  share count of 100% of the 995M authorized shares, and a very conservative
  profit margin of 30%, Elite stands to garner an increase in share price with the launch of each abuse resistant opioid product.

               



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ELTP
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ELTP News: Statement of Changes in Beneficial Ownership (4) 02/27/2017 06:48:03 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 02/27/2017 06:42:25 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 02/27/2017 06:27:37 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 02/27/2017 06:19:06 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 02/27/2017 06:10:49 PM
PostSubject
#247416  Sticky Note HERE is WHAT long term investors need to UNDERSTAND!!! Couch 03/21/17 06:12:24 PM
#239443  Sticky Note Yes IMO first SequestOx FDA Commercial approval in lasers 01/17/17 11:02:44 PM
#236265  Sticky Note Elite Pharma: The company of firsts: namtae 12/14/16 12:32:00 PM
#234937  Sticky Note THIS IS WHAT YOU NEED TO KNOW BEFORE Couch 11/30/16 03:04:07 PM
#189564  Sticky Note $ELTP SequestOx and ADF Patents lasers 03/18/16 04:29:26 AM
#185967  Sticky Note The only topic here is ELTP. IH Admin [Dan] 02/23/16 09:32:46 PM
#247845   Wrong and long since .35! Buy everything and stockboy 03/24/17 11:56:20 PM
#247844   LOL like so many unproven "facts" detailing why John_Langston 03/24/17 11:51:15 PM
#247843   Post at post like this from the TA John_Langston 03/24/17 10:50:58 PM
#247842   Thats the difference between an experienced professional and namtae 03/24/17 10:48:33 PM
#247841   Gee then it should be quite easy to John_Langston 03/24/17 10:12:31 PM
#247840   Gee then it should be quite easy to Couch 03/24/17 09:41:30 PM
#247839   An ungagged TA will tell you this" John_Langston 03/24/17 09:33:09 PM
#247838   No TA does. That is their job to Couch 03/24/17 09:28:58 PM
#247837   Might want to check on that I never Couch 03/24/17 09:26:55 PM
#247836   Yes they do. Only the gagged ones don't. John_Langston 03/24/17 09:24:52 PM
#247835   Wong be long? Is that a secret wish? Lol jour_trader 03/24/17 09:23:24 PM
#247834   I know, the PPS will never drop to John_Langston 03/24/17 09:23:05 PM
#247833   No TA does. That is their job to jour_trader 03/24/17 09:22:28 PM
#247832   ELTP throwing the .02 cents coming yesterday in Couch 03/24/17 08:57:13 PM
#247831   $0.15 is huge for Elite John_Langston 03/24/17 08:33:13 PM
#247830   It plummeted all the way from 97¢ to Couch 03/24/17 08:31:34 PM
#247829   So .068 - .97 - .151. So a mrwrn2010 03/24/17 08:31:28 PM
#247828   It plummeted all the way from 97¢ to John_Langston 03/24/17 08:29:26 PM
#247827   SEQUESTOX GREEN LIGHTED BY FDA IN DEC NASDAQ2020 03/24/17 08:21:15 PM
#247826   Gee too bad the TA didn't say it Couch 03/24/17 08:20:19 PM
#247825   Why believe the TA when they say the John_Langston 03/24/17 08:18:26 PM
#247824   Correct , GL NASDAQ2020 03/24/17 08:16:02 PM
#247823   That's not possible when the PPS could never John_Langston 03/24/17 08:12:59 PM
#247822   Must read NASDAQ2020 03/24/17 08:10:38 PM
#247820   LMAO - sure they did. lol lol lol Couch 03/24/17 07:59:25 PM
#247819   The FDA stopped Elite dead in its tracks. John_Langston 03/24/17 07:57:27 PM
#247818   No wonder Purdue is not interested in Elite, Couch 03/24/17 07:55:16 PM
#247817   Purdue no longer has any big money generating John_Langston 03/24/17 07:53:15 PM
#247816   Speculation got ELTP to 97¢. John_Langston 03/24/17 07:43:28 PM
#247815   Did you like 100 shares paint job yesterday YJ4LIFE 03/24/17 06:17:07 PM
#247814   How many Elite shares did Nasrat offer on IB_ 03/24/17 05:28:13 PM
#247813   I love those 5000 share paint jobs. Couch 03/24/17 05:24:17 PM
#247812   You mean the rusted out fluid bed nasRAT John_Langston 03/24/17 05:22:26 PM
#247811   GREEN regardless of the volume John_Langston 03/24/17 05:20:23 PM
#247809   I'm so excited about Elite moving closer to Couch 03/24/17 05:17:07 PM
#247808   I'm so excited about Elite holding $0.15 for IB_ 03/24/17 05:14:19 PM
#247807   sure March 05, 14 PR promising NDA by dr_lowenstein 03/24/17 05:09:30 PM
#247806   Selling at 18¢ is better than holding to 15¢ John_Langston 03/24/17 05:03:12 PM
#247804   6¢ will not be funny when the PPS Couch 03/24/17 05:02:12 PM
#247803   Elite has more FDA CRL issuance's per new John_Langston 03/24/17 05:01:24 PM
#247802   ELTP with a decent week of strength. Wong be long. Dubster watching 03/24/17 04:54:38 PM
#247801   Oh, how's that? Should be easy to post proof. mrwrn2010 03/24/17 04:54:38 PM
#247800   6¢ will not be funny when the PPS John_Langston 03/24/17 04:44:51 PM
#247799   Yes Nasrat was promoting the hell out of dr_lowenstein 03/24/17 04:44:03 PM
#247798   Another GREEN day that the .02's got thrown Couch 03/24/17 04:37:58 PM
#247797   Gee the facts stand - when Nasrat started Couch 03/24/17 04:34:39 PM
#247796   Gee and yet I heard the same BS Couch 03/24/17 04:33:06 PM
#247795   WOW, I just looked and Elite closed GREEN Couch 03/24/17 04:31:38 PM
#247793   Wrong The inside scoop I'd the Tmax delay namtae 03/24/17 04:29:54 PM
#247792   Zero, same amount as in the efficacy study mrwrn2010 03/24/17 04:27:35 PM
PostSubject